HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intravenous single-dose ceftriaxone treatment of chancroid.

Abstract
The antimicrobial susceptibility of Haemophilus ducreyi varies according to the geographic region. Increased resistance to trimethoprim and/or sulfamethoxazole led the Centers for Disease Control to recommend 250 mg ceftriaxone as a single intramuscular dose for chancroid. Intravenous or muscular routes of administration result in equivalent bioavailability. To avoid side effects such as syringe abscess and lidocaine intolerance, we prefer intravenous ceftriaxone therapy. The efficacy of this regimen is reported in 3 cases of chancroid. The intravenous administration of 1 g of ceftriaxone in chancroid seems to be as effective as administration by the intramuscular route, but it may lower the risk of syringe abscess, lidocaine intolerance and the emergence of resistant strains.
AuthorsA A Hartmann, P Elsner, G Burg
JournalDermatologica (Dermatologica) Vol. 183 Issue 2 Pg. 132-5 ( 1991) ISSN: 0011-9075 [Print] Switzerland
PMID1743374 (Publication Type: Case Reports, Clinical Trial, Journal Article)
Chemical References
  • Azure Stains
  • Ceftriaxone
Topics
  • Adult
  • Azure Stains
  • Ceftriaxone (administration & dosage, pharmacokinetics, therapeutic use)
  • Chancroid (diagnostic imaging, drug therapy, pathology)
  • Drug Resistance, Microbial
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: